Find information on thousands of medical conditions and prescription drugs.

Hantavirus pulmonary syndrome

Hantaviruses belong to the bunyavirus family of viruses. There are 5 genera within the bunyaviridae family: bunyavirus, phlebovirus, nairovirus, tospovirus, and hantavirus. Each is made up of negative-sensed, single-stranded RNA viruses. All these genera include arthropod-borne viruses, with the exception of hantavirus, which is a genus of rodent-borne agents. more...

Hairy cell leukemia
Hallermann Streiff syndrome
Hallux valgus
Hantavirus pulmonary...
HARD syndrome
Harlequin type ichthyosis
Hartnup disease
Hashimoto's thyroiditis
Hearing impairment
Hearing loss
Heart block
Heavy metal poisoning
HELLP syndrome
Hemifacial microsomia
Hemolytic-uremic syndrome
Hemophilia A
Hemorrhagic fever
Hepatic encephalopathy
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatocellular carcinoma
Hepatorenal syndrome
Hereditary amyloidosis
Hereditary angioedema
Hereditary ataxia
Hereditary ceroid...
Hereditary coproporphyria
Hereditary elliptocytosis
Hereditary fructose...
Hereditary hemochromatosis
Hereditary hemorrhagic...
Hereditary spastic...
Hereditary spherocytosis
Hermansky-Pudlak syndrome
Herpes zoster
Herpes zoster oticus
Hidradenitis suppurativa
Hip dysplasia
Hirschsprung's disease
Hodgkin lymphoma
Hodgkin's disease
Horner's syndrome
Horseshoe kidney
Howell-Evans syndrome
Human parvovirus B19...
Hunter syndrome
Huntington's disease
Hurler syndrome
Hutchinson Gilford...
Hutchinson-Gilford syndrome
Hydatidiform mole
Hydrops fetalis
Hypereosinophilic syndrome
Hyperimmunoglobinemia D...
Hyperkalemic periodic...
Hyperlipoproteinemia type I
Hyperlipoproteinemia type II
Hyperlipoproteinemia type...
Hyperlipoproteinemia type IV
Hyperlipoproteinemia type V
Hypertensive retinopathy
Hypertrophic cardiomyopathy
Hypokalemic periodic...
Hypoplastic left heart...
Hypothalamic dysfunction

The word hantavirus is derived from the Hantaan River, where the Hantaan virus (the etiologic agent of Korean hemorrhagic fever) was first isolated. The disease associated with Hantaan virus is called Korean hemorrhagic fever (a term that is no longer in use) or hemorrhagic fever with renal syndrome (HFRS), a term that is accepted by the World Health Organization.


Hantaviruses are a relatively newly discovered class of virus; the disease entity HFRS was first recognized by Western medicine during the Korean War in the early 1950s. In 1993, a newly-recognized species of hantavirus was found to be behind the Hantavirus cardiopulmonary syndrome (HCPS, also called HPS) caused by the Sin Nombre virus in New Mexico and other Four Corners states. In addition to Hantaan virus and Sin Nombre virus, several other hantaviruses have been implicated as etiologic agents for either HFRS or HCPS.

Geographic distribution and epidemiology

Regions especially affected by HFRS include China, the Korean Peninsula, Russia (Hantaan, Puumala and Seoul viruses), and northern and western Europe (Puumala and Dobrava viruses). Regions with the highest incidences of HCPS include Patagonian Argentina, Chile, Brazil, the United States, Canada, and Panama, where a milder form of disease that spares the heart has been recognized. The two agents of HCPS in South America are Andes virus (also called Oran, Castelo de Sonhos, Lechiguanas, Juquitiba, Araraquara, and Bermejo viruses, among many other synonyms), which is the only hantavirus that has shown (only in a few clusters of cases) an interpersonal form of transmission, and Laguna Negra virus, an extremely close relative of the previously-known Rio Mamore virus. In the U.S., minor causes of HCPS include New York virus, Bayou virus, and possibly Black Creek Canal virus.


Like other members of the bunyavirus family, hantaviruses are enveloped viruses with a genome that consists of three single-stranded RNA segments designated S (small), M (medium), and L (large). All hantaviral genes are encoded in the negative (genome complementary) sense. The S RNA encodes the nucleocapsid (N) protein. The M RNA encodes a polyprotein that is cotranslationally cleaved to yield the envelope glycoproteins G1 and G2. The L RNA encodes the L protein, which functions as the viral transcriptase/replicase. Within virions, the genomic RNAs of hantaviruses are thought to complex with the N protein to form helical nucleocapsids, the RNA component of which circularizes due to sequence complementarity between the 5' and 3' terminal sequences of each genomic segment.

Hantaviruses replicate exclusively in the host cell cytoplasm. Entry into host cells is thought to occur by attachment of virions to cellular receptors and subsequent endocytosis. Nucleocapsids are introduced into the cytoplasm by pH-dependent fusion of the virion with the endosomal membrane. Transcription of viral genes must be initiated by association of the L protein with the three nucleocapsid species. In addition to transcriptase and replicase functions, the viral L protein is also thought to have an endonuclease activity that cleaves cellular messenger RNAs (mRNAs) for the production of capped primers used to initiate transcription of viral mRNAs. As a result of this "cap snatching," the mRNAs of hantaviruses are capped and contain nontemplated 5' terminal extensions. The G1 (aka Gn) and G2 (Gc) glycoproteins form hetero-oligomers and are then transported from the endoplasmic reticulum to the Golgi complex, where glycosylation is completed. The L protein produces nascent genomes by replication via a positive-sense RNA intermediate. Hantavirus virions are believed to assemble by association of nucleocapsids with glycoproteins embedded in the membranes of the Golgi, followed by budding into the Golgi cisternae. Nascent virions are then transported in secretory vesicles to the plasma membrane and released by exocytosis.


[List your site here Free!]

Hantavirus pulmonary syndrome: a Zebra worth knowing
From American Family Physician, 9/15/02 by Kristin L. Graziano

Hantavirus pulmonary syndrome (HPS) was first recognized during the spring of 1993 after a cluster of young, previously healthy individuals who lived in the southwestern United States acquired an acute, fatal cardiopulmonary illness. The early nonspecific symptoms of these patients uniformly resembled those of other more frequently seen benign viral infections, so the severity of these infections was not initially suspected. However, the febrile prodrome was followed by rapid, diffuse, noncardiogenic pulmonary edema and hemodynamic compromise resulting in an initial case fatality rate of 76 percent. (1)

The etiologic agent was subsequently determined to be a previously unrecognized hantavirus, Sin Nombre virus (SNV), and is now known to be the predominant cause of HPS in the United States. (2) Currently, at least eight species of hantavirus are known to cause HPS in the Western Hemisphere, four of which are found in the United States. Each different virus is associated with a single rodent host species; the reservoir for SNV is the deer mouse (Peromyscus maniculatus), one of the most common small mammals in the United States. (3) Additionally, the cotton rat and rice rat are the rodent vectors in the southeastern United States for the Black Creek Canal and Bayou viruses, respectively; the whitefooted mouse carries the New York virus in the northeast.

Before 1993, illness caused by hantaviral infection had never been documented in the Americas. In Europe and Asia, infection with hantaviruses was known to cause hemorrhagic fever with renal syndrome (HFRS), an entity clinically distinct from HPS. HFRS lacks the severe pulmonary involvement characteristic of HPS and instead exhibits coagulaopathies and renal manifestations not usually seen in HPS.

Since the initial outbreak in the United States, there have been more than 280 confirmed cases of HPS, representing approximately 30 cases per year. Contrary to common opinion, HPS is not limited to the southwestern United States and has been reported in 31 states (Figure 1), (4) as well as in Canada and South America. This expanding geographic distribution is largely because of increased recognition of HPS. Fortunately, HPS remains a rare syndrome. However, because of its mild nonspecific prodrome and fulminant course, family physicians need to be aware of the epidemiology, clinical implications, clues to early diagnosis, and strategies for prevention of HPS.



The Centers for Disease Control and Prevention (CDC) tracks the latest counts and descriptive statistics of HPS in the United States. CDC data indicate that the infection predominantly affects people in rural areas, is most common in the spring and summer, and carries an overall case fatality rate close to 40 percent. The age range of confirmed case patients is 10 to 75 years, and the mean age is 37 years. (4) HPS is infrequently observed in children.

HPS is not a disease of any one racial group. Whites currently account for the majority of cases, about 77 percent. Native Americans account for about 20 percent, blacks 2 percent, and Asians 1 percent. (4) When considering ethnicity, about 11 percent of HPS cases have been reported among Hispanics.

Although initially regarded as a new infection, an early case of retrospectively identified SNV infection dates back to July 1959. (5) Additionally, reports from Native Americans living in the Southwest suggest similar episodes of illness have occurred for several decades.


SNV is transmitted to humans predominantly by inhalation of aerosolized viral particles from rodent excreta or saliva. Other potential mechanisms include direct contact with infected rodents and rodent bites, although these appear to be rare.

Person-to-person transmission of SNV has never been documented in the United States, and nosocomial infection has not occurred. (6,7) However, investigation of an HPS outbreak in Argentina caused by a different hantavirus, the Andes virus, found epidemiologic evidence supporting person-to-person transmission involving health care workers. (8)


Human illness most often results from exposure to infected rodent excreta. In an early case control study, (9) peridomestic cleaning, agricultural activities, and an increased number of rodents in or around households were shown to be associated with HPS. Entering buildings that are rarely opened or only seasonally opened may also result in exposure to mice and their excretions, contributing to infection. Local increases in precipitation are associated with HPS, presumably by triggering an increase in the rodent population. (10)

Occupationally related HPS appears to be uncommon, and travel to areas where hantavirus illness has been reported is not a risk factor for contracting the disease. The possibility of exposure during recreational activities is small and can be further reduced by limiting contact with rodents.

Clinical Manifestations

It is helpful to think of HPS as having two distinct phases. The first is a prodromal phase characterized by a relatively mild febrile illness, typically lasting three to five days. The second phase, referred to as the cardiopulmonary phase, is manifested by severe, rapidly progressive respiratory failure. Invariably, the transition from mild illness to life-threatening cardiopulmonary compromise is abrupt and dramatic.


Patients in the prodromal phase present with fever and myalgia, making prodromal HPS difficult to distinguish from other more common viral infections. Other early symptoms include gastrointestinal disturbances, headache, chills, and malaise. (4) Physical findings on initial presentation include fever, tachypnea, and tachycardia, but the remainder of the examination is usually normal.


The cardiopulmonary phase is heralded by the acute onset of pulmonary edema. Increased pulmonary capillary permeability is central to this process and may be caused by endothelial damage in the lung microvasculature. (11) The patient becomes increasingly tachypneic, develops a cough productive of copious, nonpurulent secretions, and progressive hypoxia ensues. Progression of respiratory distress is so rapid that patients usually require mechanical ventilation within 24 hours.

In severe cases, significant myocardial depression also occurs, resulting in low cardiac output and hypotension. The HPS-related hypotension has a distinctive hemodynamic profile characterized by a low cardiac index and high peripheral vascular resistance, the opposite of which is seen in septic shock caused by other pathogens. (11) Mortality is related to worsening cardiac depression, progressive respiratory failure, and subsequent acidosis culminating in fatal arrhythmias.

In patients who survive, the recovery occurs almost as quickly as the decompensation. After several days of supportive care, the cardiopulmonary processes quickly resolve, and most patients are discharged within one week of hospitalization. However, most survivors exhibit a modest degree of small airways obstruction even one year after recovery.


Early studies indicated that essentially all patients infected with SNV went through the prodromal and cardiopulmonary phases. Recently, there have been confirmed cases of SNV infection in which patients had typical prodromal symptoms but never developed cardiopulmonary involvement. (12) These reports suggest that SNV causes a wider spectrum of disease than previously thought.


HPS should be considered when patients present with fever and myalgia, especially if they have any of the aforementioned risk factors for exposure to SNV, or have recently encountered areas likely to be contaminated with rodent excretions. A lack of such history, however, does not eliminate HPS from the differential diagnosis.

Rash, rhinorrhea, pharyngitis, and conjunctivitis are rare in HPS and thus, argue against SNV infection. (13) It is important to note that rash and conjunctivitis are often seen in patients with HPS in South America. If HPS is being considered, a complete blood count (CBC) and chest radiograph should be obtained. Local health departments should be contacted for all suspected cases of HPS.


Complete Blood Count. Progressive thrombocytopenia is one of the most consistent laboratory findings in HPS, occurring in virtually all patients, and it is frequently present during the prodromal phase. Thrombocytopenia has been shown to be highly discriminatory between patients with HPS and those with other febrile illnesses. (14)

Other important hematologic abnormalities include a left-shifted leukocytosis, presence of immunoblasts, and hemoconcentration. This tetrad (thrombocytopenia, left shift, circulating immunoblasts, and hemoconcentration) is seldom seen in other viral infections. If HPS is suspected and the initial CBC is normal, it should be repeated in eight to 12 hours.

Other Laboratory Findings. Modest impairments of the coagulation profile are seen, but overt disseminated intravascular coagulation is rare. Hypoalbuminemia and lactic acidosis occur late and indicate severe disease. Although it was not reported in the 1993 outbreak, renal impairment can be a component of HPS. Abnormalities of kidney function have been predominant in disease caused by Black Creek Canal and Bayou viruses. (15)

Serologic Diagnosis. The diagnosis is confirmed by serologic identification of IgM and IgG antibodies to SNV. Assays are available at most state public health laboratories and at the CDC.


HPS has a characteristic radiologic evolution (Figure 2). Initial radiographs are most often normal, but approximately one third will exhibit mild interstitial changes. Heart size is normal, and there are no findings of pulmonary vasculature engorgement. Within 48 hours, basilar or central alveolar flooding occurs and pleural effusions are often seen. These findings differ from those seen in adult respiratory distress syndrome (ARDS), which has a more peripheral distribution and lacks the early prominent interstitial edema. (16,17) A lobar infiltrate is more consistent with bacterial pneumonia.


A variety of processes can be confused with HPS. Infectious etiologies include pneumonia, sepsis with ARDS, and acute bacterial endocarditis. Several conditions, also more commonly seen in the southwest United States, have presentations similar to HPS, including septicemic plague, tularemia, histoplasmosis, and coccidioidomycosis. Noninfectious conditions, such as myocardial infarction with pulmonary edema and Goodpasture's syndrome, should also be considered.


The probability of survival increases with early recognition and aggressive cardiopulmonary support. (18) A high index of suspicion and an awareness of the early manifestations of hantavirus infection are essential to expedite rapid transfer to an intensive care unit. Currently, there is no specific therapy available to treat HPS, therefore the cornerstone of treatment remains supportive measures. Supplemental oxygen, mechanical ventilation when indicated, fluid management, and the appropriate use of pressors are crucial to patient care. Hemodynamic monitoring with a pulmonary artery (Swan-Ganz) catheter will facilitate fluid and pressor management and can aid in establishing a preliminary diagnosis by documenting the characteristic HPS hemodynamic profile. While awaiting serologic confirmation, broad-spectrum antibiotics should be initiated.

Two potential treatments are under investigation. One is the use of extracorporeal membrane oxygenation, which exhibited favorable results in a small study of patients with severe HPS. (19) The second is the antiviral agent ribavirin (Virazole), which is currently being evaluated in a placebo-controlled clinical trial. An earlier open-label trial (20) of ribavirin failed to demonstrate a significant improvement in outcome in patients with HPS. However, this study's design makes it difficult to assess the efficacy of ribavirin.


Preventive strategies play a critical role in attempting to limit this lethal disease. The most effective way to decrease risk of HPS is to diminish human exposure to infected rodents; limiting peridomestic exposure is especially important. Measures to prevent HPS include eliminating rodents in and around households by keeping areas clean; rodent-proofing dwellings; controlling rodent populations through traps and rodenticides; properly cleaning areas of infestation; and avoiding rodents in outdoor settings.

Final Comment

Our current knowledge of HPS is in its infancy. We know relatively little about disease spectrum, pathogenesis, and potential therapeutic interventions. As the story continues to unfold, the CDC and state health departments remain excellent resources for new information.

The authors would like to acknowledge Barry D. Weiss, M.D., Department of Family Medicine, University of Arizona, for his inspiration, guidance and editorial expertise and thank Joan Kandel, D.O., for her support and review of the manuscript.

The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.


(1.) Duchin JS, Koster FT, Peters CJ, Simpson GL, Tempest B, Zaki SR, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. N Engl J Med 1994; 330:949-55.

(2.) Nichol ST, Spiropoulou CF, Morzunov S, Rollin PE, Ksiazek TG, Feldmann H, et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 1993;262:914-7.

(3.) Childs JE, Ksiazek TG, Spiropoulou CF, Krebs JW, Morzunov S, Maupin GO, et al. Serologic and genetic identification of Peromyscus maniculatus as the primary rodent reservoir for a new hantavirus in the southwestern United States. J Infect Dis 1994;169:1271-80.

(4.) National Center of Infectious Diseases, Special Pathogens Branch. All about hantavirus. Retrieved May 2002, from: hanta/hps/noframes/caseinfo.htm.

(5.) Frampton JW, Lanser S, Nichols CR. Sin Nombre virus infection in 1959 [Letter]. Lancet 1995; 346:781-2.

(6.) Wells RM, Young J, Williams RJ, Armstrong LR, Busico K, Khan AS, et al. Hantavirus transmission in the United States. Emerg Infect Dis 1997;3:361-5.

(7.) Vitek CR, Breiman RF, Ksiazek TG, Rollin PE, McLaughlin JC, Umland ET, et al. Evidence against person-to-person transmission of hantavirus to health care workers. Clin Infect Dis 1996;22:824-6.

(8.) Wells RM, Sosa Estani S, Yadon ZE, Enria D, Padula P, Pini N, et al. An unusual hantavirus outbreak in southern Argentina: person-to-person transmission? Emerg Infect Dis 1997;3:171-4.

(9.) Zeitz PS, Butler JC, Cheek JE, Samuel MC, Childs JE, Shands LA, et al. A case-control study of hantavirus pulmonary syndrome during an outbreak in the southwestern United States. J Infect Dis 1995;171:864-70.

(10.) Hjelle B, Glass GE. Outbreak of hantavirus infection in the Four Corners region of the United States in the wake of the 1997-1998 El Nino-southern oscillation. J Infect Dis 2000;181:1569-73.

(11.) Hallin GW, Simpson SQ, Crowell RE, James DS, Koster FT, Mertz GJ, et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med 1996;24:252-8.

(12.) Kitsutani PT, Denton RW, Fritz CL, Murray RA, Todd RL, Pape WJ, et al. Acute Sin Nombre hantavirus infection without pulmonary syndrome, United States. Emerg Infect Dis 1999;5:701-5.

(13.) Moolenaar RL, Dalton C, Lipman HB, Umland ET, Gallaher M, Duchin JS, et al. Clinical features that differentiate hantavirus pulmonary syndrome from three other acute respiratory illnesses. Clin Infect Dis 1995;21:643-9.

(14.) Simonsen L, Dalton MJ, Breiman RF, Hennessy T, Umland ET, Sewell CM, et al. Evaluation of the magnitude of the 1993 hantavirus outbreak in the southwestern United States. J Infect Dis 1995; 172:729-33.

(15.) Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome--Vermont, 2000. MMWR Morb Mortal Wkly Rep 2001;50:603-5.

(16.) Ketai LH, Williamson MR, Telepak RJ, Levy H, Koster FT, Nolte KB, et al. Hantavirus pulmonary syndrome: radiographic findings in 16 patients. Radiology 1994;191:665-8.

(17.) Ketai LH, Kelsey CA, Jordan K, Levin DL, Sullivan LM, Williamson MR, et al. Distinguishing hantavirus pulmonary syndrome from acute respiratory distress syndrome by chest radiography: are there different radiographic manifestations of increased alveolar permeability? J Thorac Imaging 1998;13:172-7.

(18.) Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome--Colorado and New Mexico, 1998. MMWR Morb Mortal Wkly Rep 1998;47:449-52.

(19.) Crowley MR, Katz RW, Kessler R, Simpson SQ, Levy H, Hallin GW, et al. Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med 1998;26:409-14.

(20.) Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, Ksiazek TG, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Antivir Ther 1999;4:211-9.

KRISTIN L. GRAZIANO, D.O., is a family physician on the Navajo Reservation in Tuba City, Ariz. She graduated from the College of Osteopathic Medicine of the Pacific, Pomona, Calif, and she completed a family practice residency at Community Hospital Santa Rosa, a University of California-San Francisco School of Medicine affiliate. Dr. Graziano recently completed a faculty development fellowship through the Department of Family and Community Medicine, University of Arizona College of Medicine, Tucson.

BRUCE TEMPEST, M.D., is a retired commissioned officer in the U.S. Public Health Service. Formerly, he was the chief of internal medicine at the Gallup Indian Medical Center, Gallup, N.M., and the senior clinician in internal medicine for the Indian Health Service. Dr. Tempest received his medical degree from the University of Pennsylvania School of Medicine, Philadelphia, and completed his residency in internal medicine at Philadelphia General Hospital.

Address correspondence to Kristin L. Graziano, D.O., Tuba City Indian Medical Center, Navajo Area Indian Health Service, P.O. Box 600, Tuba City, AZ 86045 (e-mail: Reprints are not available from the authors.

COPYRIGHT 2002 American Academy of Family Physicians
COPYRIGHT 2002 Gale Group

Return to Hantavirus pulmonary syndrome
Home Contact Resources Exchange Links ebay